Infectious Disease Control

Total Investment of Approx. USD 11.4 Million in Schistosomiasis Diagnostics and R&D Projects for NTDs With Partners Including Drugs & Diagnostics for Tropical Diseases and Medical & Biological Laboratories

TOKYO, March 18, 2025 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund announced today a total investment of approximatelyJPY 1.7 billion ( USD 11.4 million1) in five projects for the development of schistosomiasis diagnostics and drugs for neglected tropical diseases (NTDs).2  ...

2025-03-18 10:42 1694

Report: RSV-associated Hospitalisation Costs in Singapore Estimated at SGD 9,430 per Patient; Poses Financial Strain on At-risk Older Adults

* New findings from a recent white paper highlight the economic and healthcare burden posed by Respiratory Syncytial Virus (RSV) on at-risk older adults aged 60 years or over in select high-income APEC countriesand regions, includingAustralia, Hong Kong, Japan, and Singapore * Singapore had 3...

2025-03-11 11:45 2176

Shingles Awareness Week 2025: Shingles increases risk for heart attack and stroke; the disease also increases risk for hospitalisation more than thrice in people with diabetes

* People who have had shingles are at a 59% higher risk for heart attack and at a 35% higher risk for stroke compared to those who have not had shingles. * Adults aged 50 years or over are at high risk for shingles due to age-related decline in immunity and the risk further increases amongst t...

2025-02-26 14:45 1971

Lessons from Japan's AMR Response for the Global Community

https://iris.who.int/handle/10665/380481

2025-02-25 12:00 1675

AIM Vaccine Leverages AI to Advance mRNA Vaccine Development mRNA Shingles Vaccine Submits Clinical Trial Application

HONG KONG, Feb. 12, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published an announcement onFebruary 11, 2025, announced that its independently developed mRNA shingles vaccine has been submitted for clinical trials to the Center for Drug Evaluation (CDE) ...

2025-02-12 13:15 2842

Sasakawa Leprosy Initiative to Boost Support for Indonesia

Yohei Sasakawa, WHO Goodwill Ambassador for Leprosy Elimination, Makes Announcement on World Leprosy Day 2025 TOKYO, Jan. 25, 2025 /PRNewswire/ -- On the occasion of World Leprosy Day 2025 onJanuary 26, WHO Goodwill Ambassador for Leprosy Elimination Yohei Sasakawa announces that the Sasakawa Le...

2025-01-25 11:00 5381

Dx&Vx Presents a New Paradigm for Next-Generation Infectious Disease Response with the Development of a Universal Vaccine

- Preparing for Phase 2 Global Trials of a Ferritin Platform-Based Virus-Like Particle Universal Coronavirus Vaccine - Based on the Excellent Safety and Immune Response in Phase 1 Clinical Results, with a Plan to Extend Administration Routes and Indications SEOUL, South Korea, Jan. 13, 2025 /PRNe...

2025-01-13 22:00 3286

DIOSynVax Announces a new Advisory Board as it drives the clinical development of its NextGen Influenza Vaccines including Bird-Flu

CAMBRIDGE, England and SAN DIEGO, Jan. 9, 2025 /PRNewswire/ -- DIOSynVax, a clinical-stage biotechnology company at the forefront of developing innovative, broadly protective vaccines, built on the safety demonstrated by its "First in Human" Coronavirus vaccine trial, to announce its new portfoli...

2025-01-09 03:48 3198

Dx&Vx, From mRNA Vaccines to Nanoparticle Vaccines era of Next-Generation Vaccines

* Introduction of a Universal Coronavirus Vaccine: A robust cross-immunity effect to combat virus mutations. SEOUL, South Korea, Jan. 8, 2025 /PRNewswire/ -- The COVID-19 pandemic has fundamentally transformed global healthcare systems and vaccine technologies. The accelerated approval and rapi...

2025-01-08 22:00 2574

Docquity and HCDC Partner to Strengthen Preventive Medicine Education for Thousands of HCPs in Vietnam

Through this multi-year initiative, HCDC will tap on Docquity's digital capabilities and reach to arm over 3,000 HCPs across diverse fields with breakthroughs in preventive medicine HO CHI MINH, Vietnam, Jan. 6, 2025 /PRNewswire/ -- Docquity, Southeast Asia's largest community of healthcare prof...

2025-01-06 11:00 2769

SCG Cell Therapy partners A*STAR to accelerate RNA-based therapeutic development in Singapore

* SCG Cell Therapy signed a Memorandum of Understanding (MoU) with A*STAR Bioprocessing Technology Institute (A*STAR BTI) and Nucleic Acid Therapeutics Initiative (NATi) to advance ribonucleic acid (RNA)-based therapeutic manufacturing process development and clinical translation. * The parti...

2024-12-23 09:00 3382

GSK Leads Global Forum in Bangkok to Address Respiratory Health Challenges

GSK hosted the third annual RespiVerse Meeting on December 13 and 14 in Bangkok, Thailand. The event brought together renowned international speakers and healthcare professionals from 17 countries to address pressing global challenges in respiratory diseases, focusing on innovative solutions and ...

2024-12-17 11:59 2435

Partnership Established to Advance WHO's Road Map for Neglected Tropical Diseases 2021-2030

TOKYO and GENEVA, Dec. 11, 2024 /PRNewswire/ -- The Global Health Innovative Technology (GHIT) Fund and the World Health Organization (WHO) have signed a memorandum of understanding (MoU) to further expand their partnership to promote access to safe, effective and affordable drugs, vaccines and ...

2024-12-11 09:00 1726

Own Your Story with AwarerHOME™

Malaysia's HIV Oral Self-Test for Accessible and Confident Testing KUALA LUMPUR, Malaysia, Nov. 28, 2024 /PRNewswire/ -- Say hello to confidence and control with AwarerHOME™,Malaysia's first homegrown HIV Oral Self-Test. This accessible, no-mess, no-fuss solution offers something even more impor...

2024-11-28 16:34 2537

SK bioscience Announces Approval of Its Quadrivalent Influenza Vaccine in Indonesia

* This approval paves the way for exports to the world's fourth most populous country. * SK bioscience aims to continue to grow as a global vaccine brand beyond Korea. SEONGNAM, South Korea, Oct. 23, 2024 /PRNewswire/ -- SK bioscience , a global innovativ...

2024-10-23 15:11 2562

City microbes surviving on disinfectants, research reveals

New research shows microbes are evolving to resist cleaners used to eliminate them. It also identifies novel strains living inHong Kong that were previously only found in Antarctic desert soil. SUZHOU, China, Oct. 18, 2024 /PRNewswire/ -- After the recent pandemic, our use of disinfectants has i...

2024-10-18 17:24 3377

Centivax Selects Global CDMO BioCina to Initiate cGMP Manufacturing of Revolutionary Universal Influenza Vaccine

ADELAIDE, South Australia, Oct. 9, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced a new partnership with Centivax, Inc., for a project involving cell line development, cell banking and plasmid DNA manufact...

2024-10-09 23:37 3229

New INTREPID Alliance Antiviral Landscape Report Highlights Urgent Need to Bolster R&D Pipeline in Support of Global Pandemic Preparedness Efforts

Current mpox outbreak underscores gaps in access to medical countermeasures to help mitigate the severity of future outbreaks CAMBRIDGE, Mass., Oct. 9, 2024 /PRNewswire/ -- Today, the INTREPID Alliance, a consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral tr...

2024-10-09 19:00 1592

Healgen Scientific Receives FDA De Novo Marketing Authorization for At-Home COVID-19 and Influenza Test

Healgen Rapid Check® COVID-19/Flu A&B Antigen Test was supported through the Independent Test Assessment Program (ITAP), a National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADx®) Tech program. HOUSTON, Oct. 8, 2024 /PRNewswire/ -- Healgen Scientific LLC, a leading innovator...

2024-10-08 19:00 2436

GSK's Arexvy is a vaccine approved to protect older adults from respiratory syncytial virus (RSV) disease in Malaysia

* Adults aged 60 and over with underlying co-morbidities are at high risk of developing severe infections from RSV * Vaccine showed 82.6% overall vaccine efficacy against RSV-LRTD with 94.6% efficacy observed in adults with co-morbidities vii KUALA LUMPUR, Malaysia, Sept. 25, 2024 /PRNewswire...

2024-09-25 16:45 2793
12345 ... 35

Week's Top Stories